You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for ML 385
ML 385 is an Nrf2 inhibitor. Blocks Nrf2 downstream target gene expression. Enhances cytotoxic effects of doxorubicin (Cat. No. 2252) or Taxol (Cat. No. 1097) in non-small cell lung cancer (NSCLC). Demonstrates selectivity for NSCLC cells with KEAP1 mutations.
Compound Libraries for ML 385
Technical Data for ML 385
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for ML 385
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for ML 385
The following data is based on the product molecular weight 511.59. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||3.91 mL||19.55 mL||39.09 mL|
|2.5 mM||0.78 mL||3.91 mL||7.82 mL|
|5 mM||0.39 mL||1.95 mL||3.91 mL|
|25 mM||0.08 mL||0.39 mL||0.78 mL|
References for ML 385
References are publications that support the biological activity of the product.
Singh et al (2016) Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem.Biol. 11 3214 PMID: 27552339
If you know of a relevant reference for ML 385, please let us know.
View Related Products by Product Action
Keywords: ML 385, ML 385 supplier, ML385, Nrf2, snhibitors, cytotoxic, non-small, cell, lung, cancer, NSCLC, phenotypically, lethal, 6243, Tocris Bioscience
2 Citations for ML 385
Citations are publications that use Tocris products. Selected citations for ML 385 include:
Jeong Hwan et al (2020) Capsosiphon fulvescens Glycoproteins Enhance Probiotics-Induced Cognitive Improvement in Aged Rats. Nutrients 12 PMID: 32245093
Steven C et al (2023) Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging. Acta Neuropathol Commun 11 6 PMID: 36631900
Do you know of a great paper that uses ML 385 from Tocris? Please let us know.
Reviews for ML 385
There are currently no reviews for this product. Be the first to review ML 385 and earn rewards!
Have you used ML 385?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.